Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Musculoskeletal  |  Rheumatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Acromegaly Clinical Trials

A listing of Acromegaly medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

Acromegaly Overview Acromegaly is a rare, insidious disorder characterized by excessive secretion of growth hormone (GH) almost always from a pituitary adenoma. (Melmed NEJM 1990) Excess GH secretion in turn leads to increased levels of insulin-like growth factor-I (IGF-I), which is primarily responsible for the clinical manifestations of the disease. …

Phase N/A

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

The study was designed to answer some of the most important questions about the treatment modalities of acromegaly, the relevance of these treatment modalities to patients' clinical outcomes and the economic impact of treatment programs on patients. These answers may be of great help to the treatment of these populations …

Phase N/A

ACRODAT Prospective Evaluation Study

This is an international, multicentre, randomised, non-interventional, collaborative post marketing surveillance study to assess the clinical use of the newly developed software medical device named ACRODAT. Patients newly enrolled will be followed-up over a 2 year period. Patients will be assigned to the ACRODAT group or the Standard Practice group …

Phase N/A

Seoul National University Pituitary Disease Cohort Study

Subjects for this study will be recruited if they are: Adults, male or female aged 18 years or older Have been diagnosed with pituitary diseases

Phase N/A

Acromegaly - Before and After Treatment

Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes …

Phase N/A

Muscle in Acromegaly and Cushing's Syndrome

Prior chronic exposure to glucocorticoids or growth hormone (GH) determines fat infiltration and persistent impairment of muscle structure in "cured" patients with CS or acromegaly, respectively. All this leads to irreversible changes in muscle strength and performance, markedly affecting morbidity and quality of life of these patients. In particular, muscle …

Phase N/A

Treatment Patterns and Treatment Outcomes for Acromegaly

The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. The questionnaire will collect current information on acromegaly treatment, …

Phase N/A

Bone MicroArchitecture in Acromegaly

Growth hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) are important regulators of bone modeling and remodeling, fundamental to maintenance of normal skeletal integrity. In acromegaly, a disease characterized by longstanding exposure to excess GH and IGF-1, these hormones induce marked skeletal changes. Most dual energy X-ray absorptiometry (DXA) studies report …

Phase N/A

Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation

All the patients of either gender, diagnosed as a case of acromegaly scheduled for pituitary surgery will be enrolled. This observational study will be conducted over a period of 3 years. A written informed consent will be taken from all the patients. The clinical diagnosis will be made on the …

Phase N/A

Buccodental Manifestations in Patients With Acromegaly

Context/ study relevance: Acromegaly is a rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Growth Factor 1 (IGF-1) excess. Consequently, a dysmorphic syndrome prevailing at the level of face and extremities progressively develops …

Phase N/A